AUA: Active Surveillance Still Viable for Some Prostate Cancer Patients
medpagetoday.com     May 20, 2008            

ORLANDO, May 20 -- For men with low-risk, localized prostate cancer, active surveillance remains a viable option, but not without a "small but very real" risk, new data suggest. During 30 months of follow-up, the need for intervention could be predicted by characteristics of the first and second... [read full story]                    


View all news articles about*:
Body Cancer Cancers Health Location Male Prostate
*Newstin tag cloud displays all featured persons, associated organizations, related topics, regions and companies

View other selected articles:

                   

Researchers discover how rheumatoid arthritis causes bone loss

brightsurf.com     9 mins ago   7 related          

Study results hold implications of autoimmune disease and osteoporosis Researchers have discovered key details of how rheumatoid arthritis (RA) destroys bone, according to a study published in the Aug. 22 edition of the Journal...                    

comments

Making 'good' fat from muscle and vice versa

brightsurf.com     9 mins ago   26 related          

A surprise discovery -- that calorie-burning brown fat can be produced experimentally from muscle precursor cells in mice -- raises the prospect of new ways to fight obesity and overweight, say scientists from Dana-Farber...                    

comments

                   

New insights into the regulation of PTEN tumor suppression function

brightsurf.com     9 mins ago   4 related          

The PTEN tumor suppressor gene controls numerous biological processes including cell proliferation, cell growth and death. But PTEN is frequently lost or mutated; in fact, alteration of the gene is so common among various types...                    

comments

                   

Institute Scientist Receives Global Award To Aid The Fight Against Prostate Cancer

medicalnewstoday.com     30 mins ago   1 related          

The Institute of Cancer Research's scientist, Dr Gerhardt Attard has just been awarded a Young Investigator Award by the Prostate Cancer Foundation (PCF) for his ongoing work into developing the prostate cancer drug abiraterone.                    

comments